{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-016838","form_type":"8-K","ticker":"BCDA","cik":"0000925741","company_name":"BioCardia, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.849233+00:00","generated_at":"2026-05-21T12:05:46.564282+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BioCardia Q1 2025 net loss $2.7M; CardiAMP HF two-year data shows survival benefit; Helix FDA submission planned","bullets":["Two-year results from Phase 3 CardiAMP HF trial (presented Mar 30) showed increased survival, fewer CV events, improved QoL; significant in NTproBNP-elevated subset (p=0.02).","CardiAMP HF II confirmatory trial underway with three active sites; primary endpoint based on hierarchical analysis.","Refractory angina roll-in cohort showed 107 sec increase in exercise tolerance and 82% reduction in angina episodes at 6 months.","R&D expenses $1.5M, SG&A $1.2M; net loss $2.7M vs $2.3M YoY; cash used in ops $1.6M.","Plans to submit CardiAMP Cell Therapy for Japan PMDA consultation and Helix delivery system for FDA approval this quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-016838","json":"https://secwatch.observer/filing/0001437749-25-016838.json","markdown":"https://secwatch.observer/filing/0001437749-25-016838.md","text":"https://secwatch.observer/filing/0001437749-25-016838.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/925741/000143774925016838/0001437749-25-016838-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/925741/000143774925016838/bcda20250513_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T12:05:46.564282+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}